Karola Warzyszyńska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Karola Warzyszyńska has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Edyta Karpeta
Department of Surgical and Transplantation Nursing and Extracorporeal Therapies, Medical University of Warsaw, Warsaw, Poland
4 shared publicationsMaciej Kosieradzki
Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland
4 shared publications- Michał Zawistowski
Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland
3 shared publications Agnieszka Jałbrzykowska
Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland
2 shared publications- Maciej Kosieradzki
Department of General and Transplantation Surgery, Medical University of Warsaw, Warsaw, Poland
2 shared publications - Maurycy Jonas
Department of General Surgery, Barska Hospital, 02-315 Warsaw, Poland
2 shared publications
Latest Publications
- Open Access
- 26 July 2022
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 27, e936276-1-e936276-12
Donor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients
After renal transplantation, immunosuppressants should be administered to prevent organ rejection and prolong graft survival. One of them is tacrolimus, which is metabolized by the CYP3A enzyme family. The variability of the CYP3A5 gene in renal transplant recipients has been previously studied for its correlation with acute rejection and allogeneic kidney function. CYP3A5 enzyme is also present in the renal tissue, and its relevance has not yet been extensively investigated. This study aimed to evaluate the effect of donor and recipient CYP3A5 expression status on early and long-term transplant outcomes. Single-nucleotide polymorphism in CYP3A5 (rs776746) was analyzed in 95 kidney transplant recipients and their grafts. The effect of donor and recipient genotypes on the primary endpoint, which was the loss of the renal graft over 5-year follow-up, was assessed. The secondary endpoints were biopsy-proven acute rejection, proteinuria, delayed graft function, and renal function. Patients who received a CYP3A5*1 allele-carrying kidney (n=16) were at greater risk of graft loss (adjusted hazard ratio, 95% CI: 10.61, 2.28–49.42, P=.003) than those with the CYP3A5*3/*3 genotype (n=79). Renal CYP3A5 expression was also a predictor of acute rejection between the 2nd and 12th post-transplant months (adjusted odds ratio, 95% CI: 4.36; 1.08–17.6, P=.038) and proteinuria at different time intervals. No effect of the recipient CYP3A5 genotype was observed. The donor CYP3A5 genotype is associated with inferior transplantation outcomes. Local renal tacrolimus metabolism is a potential target for improving long-term transplantation outcomes.
- 26 July 2022
- Published by International Scientific Information, Inc. in Annals of Transplantation
- Vol. 27, e936276-1-e936276-12
Open AccessDonor CYP3A5 Expression Decreases Renal Transplantation Outcomes in White Renal Transplant Recipients
After renal transplantation, immunosuppressants should be administered to prevent organ rejection and prolong graft survival. One of them is tacrolimus, which is metabolized by the CYP3A enzyme family. The variability of the CYP3A5 gene in renal transplant recipients has been previously studied for its correlation with acute rejection and allogeneic kidney function. CYP3A5 enzyme is also present in the renal tissue, and its relevance has not yet been extensively investigated. This study aimed to evaluate the effect of donor and recipient CYP3A5 expression status on early and long-term transplant outcomes. Single-nucleotide polymorphism in CYP3A5 (rs776746) was analyzed in 95 kidney transplant recipients and their grafts. The effect of donor and recipient genotypes on the primary endpoint, which was the loss of the renal graft over 5-year follow-up, was assessed. The secondary endpoints were biopsy-proven acute rejection, proteinuria, delayed graft function, and renal function. Patients who received a CYP3A5*1 allele-carrying kidney (n=16) were at greater risk of graft loss (adjusted hazard ratio, 95% CI: 10.61, 2.28–49.42, P=.003) than those with the CYP3A5*3/*3 genotype (n=79). Renal CYP3A5 expression was also a predictor of acute rejection between the 2nd and 12th post-transplant months (adjusted odds ratio, 95% CI: 4.36; 1.08–17.6, P=.038) and proteinuria at different time intervals. No effect of the recipient CYP3A5 genotype was observed. The donor CYP3A5 genotype is associated with inferior transplantation outcomes. Local renal tacrolimus metabolism is a potential target for improving long-term transplantation outcomes.
- Open Access
- 12 May 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (4) , 960-967
Renal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients—Preliminary Report
- 12 May 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (4) , 960-967
Open AccessRenal Cyp3a5-Expressing Genotype Decreases Tacrolimus-to-Dose Ratio in Small Cohort of Renal Transplant Recipients—Preliminary Report
- Open Access
- 12 March 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 632
Development and Validation of the New Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Unbound Tacrolimus in the Plasma Ultrafiltrate of Transplant Recipients
(1) Background: Only unbound tacrolimus particles are considered to be active and capable of crossing cellular membranes. Thus, the free-drug concentration might be better associated with clinical effects than the total drug concentration used for dosage adjustment. We propose a new, fully validated online liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for unbound tacrolimus concentration measurement. (2) Methods: The determination of the unbound tacrolimus concentration in plasma ultrafiltrate was performed with the Nexera LC system with LCMS-8050 triple quadrupole MS using ascomycin as an internal standard. Chromatographic separation was made using a HypurityC18 analytical column. MS/MS with electrospray ionization and positive-ion multiple-reaction monitoring was used. The unbound tacrolimus level was determined in 36 patients after solid organ transplantation (n = 140). (3) Results: A lower limit of quantification 0.1 pg/mL was achieved, and the assay was linear between 0.1 and 20 pg/mL (R2 = 0.991). No carry-over was detected. The within-run and between-run accuracies ranged between 97.8–109.7% and 98.3–107.1%, while the greatest imprecision was 10.6% and 10.7%, respectively. Free tacrolimus in patients’ plasma ultrafiltrate varied between 0.06 and 18.25 pg/mL (median: 0.98 pg/mL). (4) Conclusions: The proposed method can be easily implemented. The significance of the unbound tacrolimus concentration needs to be investigated. This may facilitate the individualization and optimization of immunosuppressive treatment.
- 12 March 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (3) , 632
Open AccessDevelopment and Validation of the New Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Unbound Tacrolimus in the Plasma Ultrafiltrate of Transplant Recipients
(1) Background: Only unbound tacrolimus particles are considered to be active and capable of crossing cellular membranes. Thus, the free-drug concentration might be better associated with clinical effects than the total drug concentration used for dosage adjustment. We propose a new, fully validated online liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for unbound tacrolimus concentration measurement. (2) Methods: The determination of the unbound tacrolimus concentration in plasma ultrafiltrate was performed with the Nexera LC system with LCMS-8050 triple quadrupole MS using ascomycin as an internal standard. Chromatographic separation was made using a HypurityC18 analytical column. MS/MS with electrospray ionization and positive-ion multiple-reaction monitoring was used. The unbound tacrolimus level was determined in 36 patients after solid organ transplantation (n = 140). (3) Results: A lower limit of quantification 0.1 pg/mL was achieved, and the assay was linear between 0.1 and 20 pg/mL (R2 = 0.991). No carry-over was detected. The within-run and between-run accuracies ranged between 97.8–109.7% and 98.3–107.1%, while the greatest imprecision was 10.6% and 10.7%, respectively. Free tacrolimus in patients’ plasma ultrafiltrate varied between 0.06 and 18.25 pg/mL (median: 0.98 pg/mL). (4) Conclusions: The proposed method can be easily implemented. The significance of the unbound tacrolimus concentration needs to be investigated. This may facilitate the individualization and optimization of immunosuppressive treatment.
- Open Access
- 1 October 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (8) , 2403-2408
How Early Postoperative Urinary Tract Infections Affect Renal Graft Function at 1-Year Follow-up
- 1 October 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (8) , 2403-2408
Open AccessHow Early Postoperative Urinary Tract Infections Affect Renal Graft Function at 1-Year Follow-up
- Open Access
- 1 October 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (8) , 2318-2323
Early Postoperative Complications and Outcomes of Kidney Transplantation in Moderately Obese Patients
- 1 October 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (8) , 2318-2323
Open AccessEarly Postoperative Complications and Outcomes of Kidney Transplantation in Moderately Obese Patients
- 1 September 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (7) , 1979-1981
Influence of Sudden Cardiac Arrest in Deceased Kidney Donors on Organ Function After Transplantation
- 1 September 2018
- Published by Elsevier in Transplantation Proceedings
- Vol. 50 (7) , 1979-1981
Influence of Sudden Cardiac Arrest in Deceased Kidney Donors on Organ Function After Transplantation
- Open Access
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 4 (4) , 194-197
Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment – preliminary report
Aim of the study : New interferon-free direct-acting antiviral (DAA) therapy has led to major progress in hepatitis C virus (HCV) treatment. Current outcomes are promising, especially in compensated cirrhosis. However, there are reports of accelerated hepatocellular carcinoma (HCC) recurrence...
- 1 January 2017
- Published by Termedia Sp. z.o.o. in Clinical and Experimental Hepatology
- Vol. 4 (4) , 194-197
Open AccessAccelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment – preliminary report
Aim of the study : New interferon-free direct-acting antiviral (DAA) therapy has led to major progress in hepatitis C virus (HCV) treatment. Current outcomes are promising, especially in compensated cirrhosis. However, there are reports of accelerated hepatocellular carcinoma (HCC) recurrence...